Lemon Bottle

Lemon Bottle Ampoule Solution: Analytical and Regulatory Research Guide

Lemon Bottle is a trade name used online for ampoule products marketed with cosmetic or “fat-dissolving” claims. The name does not identify a peptide, a single established active pharmaceutical ingredient, or a standardized pharmacopeial material. Product descriptions commonly mention bromelain, lecithin, riboflavin, or other “natural” ingredients, but regulators have reported major discrepancies between declared and measured composition in samples obtained from different sources.

This listing is therefore presented strictly as analytical research material for identity testing, composition screening, authenticity comparison, formulation characterization, and market-surveillance studies. It is not presented as an injectable, medicine, weight-loss product, body-contouring treatment, or cosmetic for consumer use. It must not be injected, ingested, applied to people, or administered to animals.

What Researchers Should Know First

Common name	Lemon Bottle / Lemon Bottle Ampoule Solution
Material class	Branded or similarly branded multi-component ampoule material; not a peptide
Frequently declared ingredients	Bromelain, lecithin, and riboflavin are commonly named in online or package claims; presence and amount must be independently verified
Suitable research themes	Identity testing, adulteration screening, label-claim verification, formulation comparison, stability, and regulatory science
Listing configuration	10 mg × 10 vials
Use restriction	Laboratory analysis only; not for injection, clinical use, cosmetic procedures, or human or animal administration

The quantity displayed for this listing describes the catalog configuration, not an administration amount. It should never be interpreted as a treatment dose or procedural instruction. Researchers should rely on the lot-specific label, certificate of analysis, safety data, and their own identity testing before assigning a composition to any sample.

Regulatory Context and Evidence Limits

In March 2024, Swissmedic warned against products sold as “Lemon Bottle” lipolysis solution. The agency stated that no medicinal effect had been scientifically demonstrated and reported that samples from various sources did not match their declared composition. One tested sample reportedly contained only caffeine, while another lacked the ingredients listed on the package. Swissmedic treated products intended for injection as medicinal products requiring authorization and said that the examined injectable products were not authorized in Switzerland.

Swissmedic later added a statement from the Korean distributor SID Medicos. According to that statement, the distributor could not verify that the tested samples were original products and emphasized that its original Lemon Bottle Ampoule Solution was a cosmetic intended only for external use—not for lipolysis or injection. This distinction is important: products sharing a name, visual identity, or marketing language may not share the same origin or composition.

In the United States, the FDA issued a 2025 warning letter to a seller that marketed “LemonBottle Ampoule Solution” and other products with injectable lipolysis claims. The FDA characterized the products described in that warning letter as unapproved new drugs. Separately, the FDA advises that unapproved fat-dissolving injections can cause permanent scars, serious infections, skin deformities, cysts, and deep painful nodules. The agency identifies prescription deoxycholic acid sold as Kybella as the only FDA-approved fat-dissolving injectable drug, and only for reducing submental fat in adults when administered by a healthcare professional.

These regulatory findings do not prove that every item carrying the Lemon Bottle name has the same composition. They do show why brand name, package appearance, vendor description, and ingredient claims are not adequate identity tests. Any scientific work involving such material should begin with independent analytical verification and an explicit chain-of-custody record.

Appropriate Laboratory Research Applications

• Label-claim verification: testing whether declared compounds are present and whether measured amounts agree with the documentation supplied for a lot.
• Authenticity and adulteration screening: comparing chromatographic, spectroscopic, or mass-spectral profiles among reference, suspect, and market-sampled materials.
• Formulation comparison: examining pH, osmolality, color, particulates, excipients, and chemical fingerprints across batches or sources.
• Stability research: monitoring changes under defined temperature, light, freeze–thaw, and storage-time conditions.
• Regulatory science: developing screening workflows for mislabeling, counterfeit products, undeclared compounds, or inconsistent packaging.
• Method development: validating sample-preparation, separation, detection, and quantification methods using appropriate standards and controls.

Research should not be designed around an assumption that the material “dissolves fat.” That phrase is a promotional claim, not a molecular identity. If a study investigates biological effects, the tested sample must first be chemically characterized, and the protocol should identify each measured endpoint without implying clinical benefit. No result from an in vitro assay should be translated directly into a recommendation for cosmetic or medical use.

Identity and Composition Testing

A defensible analytical plan uses orthogonal methods. A single chromatographic peak, color match, or package scan cannot establish authenticity. Depending on the declared composition and the laboratory’s capabilities, a study may combine HPLC or UHPLC, liquid chromatography–mass spectrometry, gas chromatography–mass spectrometry, UV-visible spectroscopy, fluorescence measurement, Fourier-transform infrared spectroscopy, nuclear magnetic resonance, elemental analysis, and targeted enzymatic assays.

For a claimed vitamin such as riboflavin, researchers can compare retention time, absorbance, fluorescence, and mass data with a certified reference standard. Lecithin is a mixture of phospholipids rather than a single molecule, so phospholipid-class profiling and fatty-acid analysis may be more informative than a single-target assay. Bromelain is itself a mixture of proteolytic enzymes; protein content alone does not demonstrate bromelain identity or activity. Relevant work may require electrophoretic, proteomic, and activity-based measurements with suitable positive and blank controls.

Broader untargeted screening is valuable when undeclared ingredients are a concern. Researchers should define detection limits, recovery, matrix effects, and acceptance criteria before interpreting a “not detected” result. Where counterfeit or suspect products are studied, retain photographs, packaging identifiers, batch numbers, purchase records, tamper evidence, and aliquots under controlled conditions.

Quality-Control Framework

1. Document provenance. Record supplier, order date, lot or batch identifier, package markings, seal condition, and the condition on receipt.
2. Review documentation. Compare the label, certificate of analysis, safety data, and catalog description. Flag contradictory units, missing methods, generic certificates, or unexplained formulation differences.
3. Inspect without assuming identity. Note container condition, solution appearance, fill level, pH, particulates, and odor only within an appropriate laboratory safety assessment.
4. Use reference standards. Certified or otherwise qualified standards and system-suitability controls are necessary for credible identification and quantification.
5. Apply orthogonal confirmation. Confirm key findings by at least one method based on a different physical principle when feasible.
6. Report uncertainty. State sampling limitations, method performance, detection thresholds, matrix effects, and whether the tested item’s authenticity was independently established.

Handling and Laboratory Safety

Treat an unverified multi-component ampoule as material of uncertain composition. Qualified personnel should complete a written risk assessment before opening or sampling it. Wear laboratory-appropriate personal protective equipment, avoid aerosols and direct contact, and work in a containment environment appropriate for the suspected ingredients and analytical procedure. Do not rely on a cosmetic appearance, “natural” description, or online ingredient list as evidence of low risk.

Store the unopened material according to its lot-specific documentation while protecting it from unnecessary light, heat, contamination, and temperature cycling. For stability studies, define conditions prospectively and retain an untreated time-zero control. Use compatible analytical vials and clearly label all dilutions with sample identifier, solvent, concentration, preparation date, and operator.

This page does not provide reconstitution, injection, body-site, volume, needle, or administration instructions. The listed material is not sterile-certified for clinical use and is not supplied for any procedure involving a person or animal. Disposal should follow the laboratory’s rules for unknown or mixed chemical material and applicable local regulations.

How to Interpret Results

Finding one declared component does not authenticate a whole formulation. Similarly, failure to detect a target can reflect true absence, degradation, inadequate extraction, matrix suppression, or a detection limit that is too high. Report the exact analytical method and avoid categorical authenticity conclusions unless the reference material and acceptance criteria are robust.

Biological assays require additional caution. Enzyme activity, cell viability, lipid staining, inflammatory markers, or membrane effects can be influenced by pH, osmolarity, preservatives, detergents, solvents, contaminants, or multiple interacting constituents. Include vehicle, matrix, positive, negative, and cytotoxicity controls. Separate a measured biochemical effect from any claim of clinical fat reduction, cosmetic improvement, or safety.

Frequently Asked Questions

Is Lemon Bottle a peptide?

No. Lemon Bottle is a product or trade name associated with multi-component ampoule solutions. It is not the name of a defined peptide sequence.

Does this material contain bromelain, lecithin, and riboflavin?

Those ingredients are frequently declared in marketing or package information, but their presence and amount cannot be assumed. Regulators have reported composition mismatches in samples obtained from different sources. Confirm the lot with validated analytical methods.

Is Lemon Bottle approved as a fat-dissolving injection?

No such approval is established by the sources cited here. Swissmedic warned that injectable Lemon Bottle products were not authorized in Switzerland, and the FDA has acted against marketing of LemonBottle Ampoule Solution as an unapproved injectable drug in the United States.

Can researchers use the listed vial amount as an injection dose?

No. The catalog amount is only the quantity supplied. This material is for laboratory analysis and is not for injection or human or animal administration.

What is the most important first experiment?

Identity and composition testing should come before mechanism or efficacy assays. Without chemical characterization, it may be impossible to know which constituent, contaminant, or formulation property caused an observed result.

Does a label or supplier description authenticate the formulation?

No. A trade name, ingredient list or cosmetic appearance does not establish chemical identity or composition. Retain lot identifiers, assess sampling limitations and compare validated analytical results with qualified reference standards before drawing conclusions.

Does a laboratory assay establish clinical suitability?

No. Composition testing, enzyme activity or a cell-assay result cannot establish that a mixed formulation is suitable for injection, body contouring or use on people. This catalog material is restricted to laboratory analysis, and analytical findings must not be presented as administration recommendations.

Separate Catalog Identity Guides

For comparison of catalog documentation formats, researchers can review the separate identity guides for reduced glutathione, NAD+, 5-Amino-1MQ, KPV, GHK-Cu, MOTS-c, SS-31, and VIP. These links identify distinct research materials; none is asserted to be an ingredient of Lemon Bottle, a reference standard for its authentication, or a recommended combination. Establish the actual composition of the tested lot independently.

Authoritative References

1. Swissmedic. Warning about the illegal medicinal product “Lemon Bottle” lipolysis solution, including the June 2024 distributor addendum. Read the notice.
2. U.S. Food and Drug Administration. Using fat-dissolving injections that are not FDA approved can be harmful. Read the consumer update.
3. U.S. Food and Drug Administration. Warning Letter to Vivid-Scientific LLC, March 3, 2025. Read the warning letter.

Research-use notice: This material is supplied exclusively for laboratory analysis by qualified professionals. It is not a medicine, injectable, cosmetic treatment, food, dietary supplement, or veterinary product. It is not for injection, ingestion, topical use on people, diagnosis, treatment, weight loss, body contouring, or human or animal administration.